49.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$49.20
Aprire:
$49.48
Volume 24 ore:
580.63K
Relative Volume:
1.09
Capitalizzazione di mercato:
$2.36B
Reddito:
$1.10B
Utile/perdita netta:
$186.50M
Rapporto P/E:
13.20
EPS:
3.7817
Flusso di cassa netto:
$267.19M
1 W Prestazione:
+3.50%
1M Prestazione:
+6.53%
6M Prestazione:
-12.50%
1 anno Prestazione:
-19.24%
Prestige Consumer Healthcare Inc Stock (PBH) Company Profile
Nome
Prestige Consumer Healthcare Inc
Settore
Telefono
(914) 524-6800
Indirizzo
660 WHITE PLAINS RD., TARRYTOWN, NY
Compare PBH vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare Inc
|
49.92 | 2.36B | 1.10B | 186.50M | 267.19M | 3.7817 |
|
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Prestige Consumer Healthcare Inc Stock (PBH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-09-24 | Aggiornamento | Sidoti | Neutral → Buy |
| 2024-12-09 | Downgrade | Sidoti | Buy → Neutral |
| 2024-06-21 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2022-11-17 | Iniziato | Canaccord Genuity | Buy |
| 2022-05-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-05-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-08-07 | Downgrade | DA Davidson | Buy → Neutral |
| 2020-06-29 | Aggiornamento | Sidoti | Neutral → Buy |
| 2020-04-14 | Downgrade | Jefferies | Buy → Hold |
| 2020-04-07 | Ripresa | Sidoti | Neutral |
| 2020-03-26 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-24 | Iniziato | Oppenheimer | Perform |
| 2020-03-19 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2019-01-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2017-12-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-06-02 | Aggiornamento | Jefferies | Underperform → Hold |
| 2017-05-22 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2016-12-27 | Reiterato | B. Riley & Co. | Buy |
| 2016-11-17 | Iniziato | Gabelli & Co | Buy |
| 2016-08-12 | Aggiornamento | Sidoti | Neutral → Buy |
| 2016-03-08 | Iniziato | KeyBanc Capital Mkts | Overweight |
| 2016-02-05 | Iniziato | Piper Jaffray | Overweight |
| 2015-11-30 | Downgrade | Jefferies | Hold → Underperform |
| 2014-04-28 | Reiterato | B. Riley & Co. | Buy |
| 2014-04-28 | Reiterato | Oppenheimer | Outperform |
| 2013-07-09 | Iniziato | B. Riley & Co. | Buy |
Mostra tutto
Prestige Consumer Healthcare Inc Borsa (PBH) Ultime notizie
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? - Zacks Investment Research
Prestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results - Yahoo Finance
How InvestingPro spotted Prestige Healthcare’s 43% stock decline By Investing.com - Investing.com
Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis $PBH - MarketBeat
What Does the Guidance Raise Mean for Prestige Consumer (NYSE:PBH)? - Kalkine Media
Prestige Consumer Healthcare stock falls 11% on Q4 revenue decline - scanx.trade
Prestige Consumer Q1FY27 Results: Revenue rises 6.5% to $266 million - scanx.trade
Transcript: Prestige Consumer Q1 2027 Earnings Conference Call - Benzinga
Prestige Consumer Latest Results: Sales guidance rises to $1.29B-$1.315B - scanx.trade
Prestige Consumer Healthcare acquires Breathe Right for $1.045bn - scanx.trade
Prestige prices $400 million 6.25% notes due 2034 - scanx.trade
Best Value Stocks to Buy for October 1st - Zacks Investment Research
PBH vs. NEOG: Which Stock Is the Better Value Option? - Zacks Investment Research
More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey Finds – Company AnnouncementFT.com - Financial Times
More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey Finds – Company AnnouncementFT.com - Financial Times
Has Prestige Consumer Healthcare (PBH) Fallen Far Enough On Earnings? - Yahoo Finance
Prestige Consumer Healthcare (PBH) Could Be 30% Undervalued After Its 2027 Targets - Yahoo Finance
Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow - Yahoo Finance
Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow - TradingView
Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow - TradingView
Prestige Consumer Healthcare at small-cap virtual conference: growth plan intact - Investing.com India
Prestige Consumer Healthcare at small-cap virtual conference: growth plan intact - Investing.com
A Look at Prestige Consumer Healthcare Inc (PBH) After 3.8% Decl - GuruFocus
Prestige Consumer Healthcare Inc. (PBH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Prestige Consumer Healthcare stock gains ahead of Sidoti event - AD HOC NEWS
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: 50% Upside Potential Amid Steady Revenue Growth - DirectorsTalk Interviews
Prestige Consumer Healthcare Inc (PBH) Shares Fall 3.2% -- What GF Score of 65 Tells Investors - GuruFocus
PBH: Portfolio expansion and brand integration drive growth, with Clear Eyes recovery a key focus - TradingView
Prestige Consumer Healthcare at Barclays conference: growth via niche brands - Investing.com Canada
Prestige Consumer Healthcare at Barclays conference: growth via niche brands - investing.com
Prestige Consumer Healthcare at Barclays conference: growth via niche brands - Investing.com India
How InvestingPro Fair Value spotted Prestige Healthcare’s 43% drop By Investing.com - Investing.com India
How InvestingPro Fair Value spotted Prestige Healthcare’s 43% drop By Investing.com - Investing.com
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference - manilatimes.net
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference - Yahoo! Finance Canada
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference - Moomoo
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference - Yahoo Finance
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Assessing a Promising 29.74% Potential Upside - DirectorsTalk Interviews
Is This the Right Time to Add PBH Stock to Your Portfolio? - TradingView
Is This the Right Time to Add PBH Stock to Your Portfolio? - Yahoo Finance
Precision Trading with Prestige Consumer Healthcare Inc. (PBH) Risk Zones - Stock Traders Daily
Prestige Consumer Healthcare stock holds steady as investors watch valuation and growth - AD HOC NEWS
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test - Financial Times
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Exploring A 29% Upside Potential - DirectorsTalk Interviews
PBH vs. SYK: Which Stock Is the Better Value Option? - Yahoo Finance
Prestige Consumer Healthcare Inc. (PBH) Investor Outlook: Exploring a 32% Upside Potential - DirectorsTalk Interviews
Nearly 40,000 Bottles of Eye Drops Recalled Nationwide - Yahoo
40,000 eye drop bottles recalled over potential contamination - Oman Observer
Nearly 40,000 eye drop bottles are recalled over potential contamination - The Seattle Times
40,000 bottles of eye drops across the US recalled over issues with sterility of product - inkl
Prestige Consumer Healthcare Inc Azioni (PBH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prestige Consumer Healthcare Inc Azioni (PBH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zerillo Jeffrey | Officer |
May 11 '26 |
Proposed Sale |
52.28 |
351 |
18,350 |
0 |
| Zerillo Jeffrey | Officer |
May 07 '26 |
Proposed Sale |
54.36 |
305 |
16,580 |
0 |
| Zerillo Jeffrey | Senior VP Operations |
May 07 '26 |
Sale |
54.36 |
305 |
16,580 |
42,161 |
| Zerillo Jeffrey | Officer |
May 06 '26 |
Proposed Sale |
54.99 |
1,207 |
66,374 |
0 |
| Zerillo Jeffrey | Officer |
May 05 '26 |
Proposed Sale |
55.32 |
346 |
19,141 |
0 |
| Zerillo Jeffrey | Senior VP Operations |
May 05 '26 |
Sale |
55.32 |
346 |
19,141 |
44,334 |
| Zerillo Jeffrey | Senior VP Operations |
May 05 '26 |
Sale |
54.99 |
1,207 |
66,373 |
42,820 |
| Zerillo Jeffrey | Senior VP Operations |
Feb 11 '26 |
Sale |
65.93 |
1,000 |
65,930 |
41,048 |
| Zerillo Jeffrey | Officer |
Feb 11 '26 |
Proposed Sale |
65.93 |
1,000 |
65,930 |
0 |
| Zerillo Jeffrey | Senior VP Operations |
Dec 01 '25 |
Sale |
60.00 |
281 |
16,860 |
42,048 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):